📊 KYTX Key Takeaways
Is Kyverna Therapeutics, Inc. (KYTX) a Good Investment?
Kyverna is a pre-revenue biotech company with accelerating cash burn (-$41.6M annually) and only ~9 months of runway at current burn rate. While the balance sheet appears strong, negative trends in profitability (losses worsening YoY) and lack of revenue-generating products create unsustainable economics requiring dilutive capital raises.
Kyverna is a pre-revenue biotech with deeply negative profitability and rising operating losses, leading to substantial cash burn. While liquidity is strong with no debt and a high current ratio, the current cash balance appears insufficient against the burn rate, implying likely future financing needs. Absent revenue visibility or clear near-term inflection in operating efficiency, fundamentals skew unfavorable.
Kyverna Therapeutics, Inc. Key Strengths (KYTX)
- Strong balance sheet with $257M total assets and $195.6M stockholders' equity
- Excellent liquidity position (8.15x current ratio) to fund near-term operations
- Zero debt burden eliminates refinancing and interest coverage risk
- Strong liquidity with a 7.75x current ratio
- Zero debt and minimal interest burden
- Low capital intensity (negligible capex) offers flexibility
KYTX Stock Risks: Kyverna Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no commercial products generating revenue
- Unsustainable cash burn of -$41.6M annually against only $32.2M cash reserves (~9 months runway)
- Deteriorating financial performance with losses worsening YoY (-26.5% net income decline)
- Will require dilutive capital raises to extend runway and fund development
- Biotech execution risk with no visibility into clinical trial success or commercialization timeline
- No revenue with persistent, widening operating and net losses
- High operating cash burn (-$153.7M) implying short runway without new capital
- Negative ROE/ROA indicate poor capital efficiency
Key Metrics to Watch
- Monthly cash burn rate and time to next funding event
- Clinical program advancement and regulatory milestone achievements
- Cash position trajectory and any announced capital raises or partnership deals
- Quarterly operating cash burn (CFO)
- Cash & equivalents and runway duration
Kyverna Therapeutics, Inc. (KYTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.15x current ratio provides a solid financial cushion.
KYTX Profit Margin, ROE & Profitability Analysis
KYTX vs Healthcare Sector: How Kyverna Therapeutics, Inc. Compares
How Kyverna Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kyverna Therapeutics, Inc. Stock Overvalued? KYTX Valuation Analysis 2026
Based on fundamental analysis, Kyverna Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kyverna Therapeutics, Inc. Balance Sheet: KYTX Debt, Cash & Liquidity
KYTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kyverna Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.33 indicates the company is currently unprofitable.
KYTX Revenue Growth, EPS Growth & YoY Performance
Kyverna Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KYTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kyverna Therapeutics, Inc. (CIK: 0001994702)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KYTX
What is the AI rating for KYTX?
Kyverna Therapeutics, Inc. (KYTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KYTX's key strengths?
Claude: Strong balance sheet with $257M total assets and $195.6M stockholders' equity. Excellent liquidity position (8.15x current ratio) to fund near-term operations. ChatGPT: Strong liquidity with a 7.75x current ratio. Zero debt and minimal interest burden.
What are the risks of investing in KYTX?
Claude: Pre-revenue stage with no commercial products generating revenue. Unsustainable cash burn of -$41.6M annually against only $32.2M cash reserves (~9 months runway). ChatGPT: No revenue with persistent, widening operating and net losses. High operating cash burn (-$153.7M) implying short runway without new capital.
What is KYTX's revenue and growth?
Kyverna Therapeutics, Inc. reported revenue of N/A.
Does KYTX pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
Where can I find KYTX SEC filings?
Official SEC filings for Kyverna Therapeutics, Inc. (CIK: 0001994702) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KYTX's EPS?
Kyverna Therapeutics, Inc. has a diluted EPS of $-0.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KYTX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Kyverna Therapeutics, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KYTX stock overvalued or undervalued?
Valuation metrics for KYTX: ROE of -20.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KYTX's AI grade for 2026?
Our dual AI analysis gives Kyverna Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KYTX's free cash flow?
Kyverna Therapeutics, Inc.'s operating cash flow is $-41.6M, with capital expenditures of $5.0K.
How does KYTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -20.3% (avg: 15%), current ratio 8.15 (avg: 2).